Correlation Of Ki67 with ER, PR, Her2neu and other Prognostic Factors In Breast Carcinoma.

  • Menka Khanna SGRDIMSAR, Amritsar, Punjab
  • Manisha Sharma
  • Mridu Manjari
  • Kiranjot Kaur
  • Saumil Garg
  • Saloni Goyal
Keywords: Breast Cancer, Immunohistochemistry, Ki67, ER, PR, Her2neu

Abstract

Background: Breast cancer is the most common malignancy occurring in females, accounting for 23% of all malignant tumors.1 Various predictive and prognostic factors affect tumor progression. In addition to estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (Her2neu) overexpression, recently Ki67, a proliferative marker has been recognised as an important predictive and prognostic marker in many studies. The aim of the present study is to find the correlation of Ki67 proliferation index with ER PR and Her2neu status and with other clinicopathological parameters.Methods: The study was conducted on 70 cases of breast cancer received as mastectomy or lumpectomy specimens. The histopathological grading of the breast carcinoma was done according to the Nottingham modification of the Bloom Richardson grading system. IHC was performed by using antibodies against the estrogen receptors (ER), the progesterone receptors (PR), Her2neu and Ki67. An attempt was made to find a correlation between ER, PR, Her2neu and Ki67 expression with the various clinicopathological parameters.Result: ER PR expression was seen to be decreased with increase in Ki67 positivity. Ki67 proliferation index when correlated with the various clinicopathological parameters (grade, lymph node metastasis and size of tumor) it was concluded that as the Ki67 positivity increased the prognosis became poorer.Conclusion: It was concluded that Ki67 can be considered as a new prognostic marker in addition to ER PR and Her2neu and is associated with a poor prognosis. 

Author Biography

Menka Khanna, SGRDIMSAR, Amritsar, Punjab
Associate Professor, Department Of Pathology

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer staristics. CA Cancer J Clin 2011;61:69–90.
2. Khokhar K. Breast Cancer in India: Where do we stand and where do we go. Asian Pacific J Cancer Prev 2012;13(10):4861-6.
3. Shetty P. India faces growing breast cancer epidemic. The Lancet 2012;379(9820):992-3.
4. Moutafoff C, Coutant C, Bezu C. Prognostic and predictive factors in multifocal breast carcinoma. Gynecol Obstet Fertil 2011;39:425–32.
5. Mahmood H, Faheem M, Mahmood S. Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan. Asian Pac J Cancer Prev 2015;16:1019–24.
6. Ariga R, Zarif A, Korasick J. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11:278–80.
7. Baulies S, Cusido M, Gonzalez-Cao M. Hormone receptor and HER2 status: the only predictive factors of response to neoadjuvant chemotherapy in breast cancer. J Obstet Gynaecol 2015:35(5):485-9.
8. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta 2015;1856(1):73-85.
9. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227–38.
10. Wong SY, Kernohan NM, Walker F. Breast cancers with extremely high estrogen receptor protein status. Histopathology 1990;16:125–32.
11. Liu M, Lawson G, Delos M. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations. Head Neck 2003;25:280–8.
12. Fasching PA, Heusinger K, Haeberle L. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011;11(486):6-8.
13. Gobbin H, Rocha RM, Nunes CB. Predictive factors of breast cancer evaluated by immunohistochemistry. J Bras Pathol Med Lab 2008;44(22):131-40.
14. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 2011;22:1736-47.
15. Shokouh TZ, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Gradeand Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.Medicine 2015;94(32):1359-65.

16. Khokhar A. Breast cancer in India: where do we stand and where do we go? Asian Pac J Cancer Prev 2012;13:4861–6.
17. Peng Y. Potential prognostic tumor biomarkers in triple-negative breast carcinoma. Beijing da Xue Xue Bao 2012;44:666-72.
18. Han JS, Cao D, Molberg KH, Sarode VR, Rao R. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol 2011;135:2307-12.
19. Rhee J, Han SW, Oh DY, Kim JH, Im SA. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008.8:307-9.
20. Lukashina MI, Glukhova EI, Zhukova LG, Ermilova VD, Bogatyrev VN, Baryshikov A. Her-2/Nu, Ki-67 expression and ploidy in breast carcinoma. Arkh Pathol 2003;65(5):25-9.
21. Li H, Han X, Liu Y, Liu G, Dong G. Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer. Oncol Lett 2015;9(1):149-52.
22. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007;7:203-6.
23. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008;8:307-10.
24. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212–20.
25. Jones RL, Salter J, Hern RA, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010;119:315–23.
26. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996;2:585–92.
27. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275–81.
28. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011 Mar 2;13(2):R22.
Published
2016-12-13
Section
Original Article

Most read articles by the same author(s)

1 2 > >>